MarketWatch.com - Top Stories

Sarepta Therapeutics’ stock falls after patient dies of liver failure

The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.

Mar 18, 2025 - 14:58
 0
Sarepta Therapeutics’ stock falls after patient dies of liver failure
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
Read More

Tags:

Previous Article

Households plans for long-term care, but those plans may not reflect reality

Next Article

Prediction: These 2 Stocks Will Outperform the Market Through 2030

Related Posts

Should I take money from my Roth IRA or leave it to my heirs? 

Should I take money from my Roth IRA or leave it to my ...

Mar 17, 2025  0

Why ditching the penny may not cost Americans much

Why ditching the penny may not cost Americans much

Feb 10, 2025  0

What else can Canada and Mexico do to avoid Trump’s tariffs? America’s neighbors may slap new tariffs on China.

What else can Canada and Mexico do to avoid Trump’s tar...

Feb 28, 2025  0